EyePoint (EYPT) FCF Margin (2010 - 2026)
EyePoint (EYPT) posted FCF Margin of 11587.36% for Q1 2026, down 5.28% sequentially from 11006.61% in Q4 2025, and down 1136994.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) FCF Margin (2010 - 2026) Analysis & Trends
EyePoint has reported FCF Margin for 17 years, with the latest figure at 11587.36% in Q1 2026.
- Quarterly FCF Margin fell 1136994.0% year-over-year to 11587.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3557.11% (down 328636.0% YoY) and the FY2025 annual result came in at 775.84%, down 47478.0% from the prior year.
- FCF Margin retreated to 11587.36% in Q1 2026 per EYPT's latest filing, from 11006.61% in the prior quarter.
- Over five years, FCF Margin peaked at 631.6% in Q2 2023 and troughed at 11587.36% in Q1 2026.
- A 5-year average of 1872.99% and a median of 218.5% in 2022 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2026: FCF Margin jumped 79884 bps in 2023, then slumped 1136994 bps in 2026.
- Over 5 years, FCF Margin stood at 125.06% in 2022, then tumbled by 32 bps to 164.73% in 2023, then plunged by 96 bps to 323.43% in 2024, then plunged by 3303 bps to 11006.61% in 2025, then dropped by 5 bps to 11587.36% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 11587.36%, 11006.61%, and 6146.79% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -12,310.06% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12,310.06% |
| Mar 31, 2026 | -12,055.75% |
| Dec 31, 2025 | -10,650.48% |
| Sep 30, 2025 | -6,226.92% |
| Jun 30, 2025 | -1,196.49% |
| Mar 31, 2025 | -218.36% |
| Dec 31, 2024 | -328.04% |
| Sep 30, 2024 | -385.80% |
| Jun 30, 2024 | -222.41% |
| Mar 31, 2024 | -277.00% |
| Dec 31, 2023 | -171.03% |
| Sep 30, 2023 | -111.33% |
| Jun 30, 2023 | 621.93% |
| Mar 31, 2023 | -225.42% |
| Dec 31, 2022 | -125.06% |
| Sep 30, 2022 | -143.17% |
| Jun 30, 2022 | -167.24% |
| Mar 31, 2022 | -218.50% |
| Dec 31, 2021 | -144.39% |
| Sep 30, 2021 | -87.40% |